Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database

References

• Park JH, Anderson WF, Gail MH. Improvements in US Breast Cancer Survival and Proportion Explained by Tumor Size and Estrogen-Receptor Status. Jco. 2015;33:2870–2876.
   PubMed Web of Science ®Google Scholar
• Jensen AR, Storm HH, Moller S, et al. Validity and representativity in the Danish Breast Cancer Cooperative Group – a study on protocol allocation and data validity from one county to a multi-centre database. Acta Oncol. 2003;42:179–185.
   PubMed Web of Science ®Google Scholar
• Christiansen P, Ejlertsen B, Jensen MB, et al. Danish Breast Cancer Cooperative Group. Clin Epidemiol. 2016;8:445–449.
   PubMed Web of Science ®Google Scholar
• Moller S, Jensen MB, Ejlertsen B, et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008;47:506–524.
   PubMed Web of Science ®Google Scholar
• Christiansen P, Al-Suliman N, Bjerre K, et al. Recurrence pattern and prognosis in low-risk breast cancer patients – data from the DBCG 89-A programme. Acta Oncol. 2008;47:691–703.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29:541–549.
   PubMed Web of Science ®Google Scholar
• Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, et al. Data Resource Profile: The Danish National Prescription Registry. Int J Epidemiol. 2017;46:798–798f.
   PubMed Web of Science ®Google Scholar
• Ehrenstein V, Antonsen S, Pedersen L. Existing data sources for clinical epidemiology: Aarhus University Prescription Database. Clin Epidemiol. 2010;2:273–279.
   PubMedGoogle Scholar
• Johannesdottir SA, Horvath-Puho E, Ehrenstein V, et al. Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions. Clin Epidemiol. 2012; 4:303–313.
   PubMedGoogle Scholar
• Winther Lietzen L, Ahern T, Christiansen P, et al. Glucocorticoid prescriptions and breast cancer recurrence: a Danish nationwide prospective cohort study. Ann Oncol. 2014;25:2419–2425.
   PubMed Web of Science ®Google Scholar
• Sørensen G, Ganz P, Cole S, et al. Use of beta blockers, ACE inhibitors, angiotensin II receptor blockers and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. Jco. 2013;31:2265–2272.
   PubMed Web of Science ®Google Scholar
• Ahern TP, Pedersen L, Tarp M, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst. 2011;103:1461–1468.
   PubMed Web of Science ®Google Scholar
• Cronin-Fenton DP, Heide-Jorgensen U, Ahern TP, et al. Low-dose aspirin, nonsteroidal anti-inflammatory drugs, selective COX-2 inhibitors and breast cancer recurrence. Epidemiology. 2016; 27:586–593.
   PubMed Web of Science ®Google Scholar
• Cronin-Fenton DP, Heide-Jorgensen U, Ahern TP, et al. Opioids and breast cancer recurrence: a Danish population-based cohort study. Cancer. 2015;121:3507–3514.
   PubMed Web of Science ®Google Scholar
• Biggar RJ, Andersen EW, Kroman N, et al. Breast cancer in women using digoxin: tumor characteristics and relapse risk. Breast Cancer Res. 2013;15:R13.
   PubMed Web of Science ®Google Scholar
• Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167:492–499.
   PubMed Web of Science ®Google Scholar
• Lash TL, Pedersen L, Cronin-Fenton D, et al. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer. 2008;99:616–621.
   PubMed Web of Science ®Google Scholar
• Demierre MF, Higgins PD, Gruber SB, et al. Statins and cancer prevention. Nat Rev Cancer. 2005;5:930–942.
   PubMed Web of Science ®Google Scholar
• Kwan ML, Habel LA, Flick ED, et al. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat. 2008;109:573–579.
   PubMed Web of Science ®Google Scholar
• Chae YK, Valsecchi ME, Kim J, et al. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest. 2011;29:585–593.
   PubMed Web of Science ®Google Scholar
• Cardwell CR, Hicks BM, Hughes C, et al. Statin use after diagnosis of breast cancer and survival: a population-based cohort study. Epidemiology. 2015;26:68–78.
   PubMed Web of Science ®Google Scholar
• Boudreau DM, Yu O, Chubak J, et al. Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat. 2014;144:405–416.
   PubMed Web of Science ®Google Scholar
• Murtola TJ. Impact of statins on genitourinary cancer outcomes: the promise and the challenge. J Urol. 2014;191:889–890.
   PubMed Web of Science ®Google Scholar
• Nickels S, Vrieling A, Seibold P, et al. Mortality and recurrence risk in relation to the use of lipid-lowering drugs in a prospective breast cancer patient cohort. PLoS One. 2013;8:e75088.
   PubMed Web of Science ®Google Scholar
• Mc Menamin UC, Murray LJ, Hughes CM, et al. Statin use and breast cancer survival: a nationwide cohort study in Scotland. BMC Cancer. 2016;16:600.
   PubMed Web of Science ®Google Scholar
• Regan MM, Neven P, Giobbie-Hurder A, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol. 2011;12:1101–1108.
   PubMed Web of Science ®Google Scholar
• Borgquist S, Giobbie-Hurder A, Ahern TP, et al. Cholesterol, cholesterol-lowering medication use, and breast cancer outcome in the BIG 1-98 study. Jco. 2017;35:1179–1188.
   PubMed Web of Science ®Google Scholar
• Borgquist S, Jogi A, Ponten F, et al. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer. Breast Cancer Res. 2008;10:R79.
   PubMed Web of Science ®Google Scholar
• Ahern TP, Lash TL, Damkier P, et al. Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncol. 2014;15:e461–e468.
   PubMed Web of Science ®Google Scholar
• Emilsson L, Garcia-Albeniz X, Logan RW, et al. Examining bias in studies of statin treatment and survival in patients with cancer. JAMA Oncol. 2017 [Aug 20]. DOI:10.1001/jamaoncol.2017.2752
   PubMed Web of Science ®Google Scholar
• Lash TL, Riis AH, Ostenfeld EB, et al. Associations of statin use with colorectal cancer recurrence and mortality in a Danish cohort. Am J Epidemiol. 2017;186:679–687.
   PubMed Web of Science ®Google Scholar
• Elwood PC, Gallagher AM, Duthie GG, et al. Aspirin, salicylates, and cancer. Lancet. 2009;373:1301–1309.
   PubMed Web of Science ®Google Scholar
• Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493–501.
   PubMed Web of Science ®Google Scholar
• Allen JE, Patel AS, Prabhu VV, et al. COX-2 drives metastatic breast cells from brain lesions into the cerebrospinal fluid and systemic circulation. Cancer Res. 2014;74:2385–2390.
   PubMed Web of Science ®Google Scholar
• Choi BH, Chakraborty G, Baek K, et al. Aspirin-induced Bcl-2 translocation and its phosphorylation in the nucleus trigger apoptosis in breast cancer cells. Exp Mol Med. 2013;45:e47.
   PubMed Web of Science ®Google Scholar
• Holmes MD, Chen WY, Li L, et al. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28:1467–1472.
   PubMed Web of Science ®Google Scholar
• Murray LJ, Cooper JA, Hughes CM, et al. Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case–control study in a breast cancer cohort from the UK Clinical Practice. Breast Cancer Res. 2014;16:R34.
   PubMed Web of Science ®Google Scholar
• Blair CK, Sweeney C, Anderson KE, et al. NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat. 2007;101:191–197.
   PubMed Web of Science ®Google Scholar
• Kwan ML, Habel LA, Slattery ML, et al. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control. 2007;18:613–620.
   PubMed Web of Science ®Google Scholar
• Li Y, Brasky TM, Nie J, et al. Use of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev. 2012;21:239–242.
   PubMed Web of Science ®Google Scholar
• Barron TI, Flahavan EM, Sharp L, et al. Recent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I-III breast cancer: a nationwide population-based cohort study. Cancer Res. 2014;74:4065–4077.
   PubMed Web of Science ®Google Scholar
• Holmes MD, Olsson H, Pawitan Y, et al. Aspirin intake and breast cancer survival – a nation-wide study using prospectively recorded data in Sweden. BMC Cancer. 2014;14:391–2407.
   PubMed Web of Science ®Google Scholar
• Barron TI, Murphy LM, Brown C, et al. De Novo post-diagnosis aspirin use and mortality in women with stage I–III breast cancer. Cancer Epidemiol Biomarkers Prev. 2015;24:898–904.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379:1591–1601.
   PubMed Web of Science ®Google Scholar
• Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13:518–527.
   PubMed Web of Science ®Google Scholar
• Fraser DM, Sullivan FM, Thompson AM, et al. Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br J Cancer. 2014;111:623–627.
   PubMed Web of Science ®Google Scholar
• Mc Menamin UC, Cardwell CR, Hughes CM, et al. Low-dose aspirin use and survival in breast cancer patients: a nationwide cohort study. Cancer Epidemiol. 2017;47:20–27.
   PubMed Web of Science ®Google Scholar
• Wernli KJ, Hampton JM, Trentham-Dietz A, et al. Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidem Drug Safe. 2011;20:131–137.
   PubMed Web of Science ®Google Scholar
• Bardia A, Ebbert JO, Vierkant RA, et al. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst. 2007;99:881–889.
   PubMed Web of Science ®Google Scholar
• Nishihara R, Lochhead P, Kuchiba A, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 2013;309:2563–2571.
   PubMed Web of Science ®Google Scholar
• Smith C, Teitler M. Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc Drugs Ther. 1999;13:123–126.
   PubMed Web of Science ®Google Scholar
• Powe DG, Voss MJ, Habashy HO, et al. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. Breast Cancer Res Treat. 2011;130:457–463.
   PubMed Web of Science ®Google Scholar
• Powe DG, Voss MJ, Zanker KS, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010;1:628–638.
   PubMed Web of Science ®Google Scholar
• Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. Jco. 2011; 29:2645–2652.
   PubMed Web of Science ®Google Scholar
• Barron TI, Connolly RM, Sharp L, et al. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol. 2011; 29:2635–2644.
   PubMed Web of Science ®Google Scholar
• Ganz PA, Habel LA, Weltzien EK, et al. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat. 2011;129:549–556.
   PubMed Web of Science ®Google Scholar
• Cardwell CR, Coleman HG, Murray LJ, et al. Beta-blocker usage and breast cancer survival: a nested case–control study within a UK Clinical Practice Research Datalink cohort. Int J Epidemiol. 2013;42:1852–1861.
   PubMed Web of Science ®Google Scholar
• Cardwell CR, Pottegard A, Vaes E, et al. Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts. Breast Cancer Res. 2016;18:119.
   PubMed Web of Science ®Google Scholar
• Barron TI, Sharp L, Visvanathan K. Beta-adrenergic blocking drugs in breast cancer: a perspective review. Ther Adv Med Oncol. 2012;4:113–125.
   PubMed Web of Science ®Google Scholar
• Koh WP, Yuan JM, Van Den BD, et al. Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis. 2005;26:459–464.
   PubMed Web of Science ®Google Scholar
• Babacan T, Balakan O, Kuzan TY, et al. The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+ breast cancer patients. J Buon. 2015;20:50–56.
   PubMed Web of Science ®Google Scholar
• Chae YK, Brown EN, Lei X, et al. Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes. J Cancer. 2013;4:549–556.
   PubMed Web of Science ®Google Scholar
• Holmes MD, Hankinson SE, Feskanich D, et al. Beta blockers and angiotensin-converting enzyme inhibitors' purported benefit on breast cancer survival may be explained by aspirin use. Breast Cancer Res Treat. 2013;139:507–513.
   PubMed Web of Science ®Google Scholar
• Sendur MA, Aksoy S, Yaman S, et al. Efficacy of angiotensin-receptor blockers on demographic and clinico-pathological characteristics of breast cancer. Breast. 2012;21:419–420.
   PubMed Web of Science ®Google Scholar
• Raimondi S, Botteri E, Munzone E, et al. Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: systematic review and meta-analysis. Int J Cancer. 2016;139:212–219.
   PubMed Web of Science ®Google Scholar
• Cardwell CR, Mc Menamin UC, Hicks BM, et al. Drugs affecting the renin–angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts. BMC Med. 2014;12:28–7015-12-28.
   PubMed Web of Science ®Google Scholar
• Spera G, Fresco R, Fung H, et al. Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study. Ann Oncol. 2017;28:1836–1841.
   PubMed Web of Science ®Google Scholar
• Ferrand N, Stragier E, Redeuilh G, et al. Glucocorticoids induce CCN5/WISP-2 expression and attenuate invasion in oestrogen receptor-negative human breast cancer cells. Biochem J. 2012; 447:71–79.
   PubMed Web of Science ®Google Scholar
• Sorensen GV, Cronin-Fenton DP, Sorensen HT, et al. Use of glucocorticoids and risk of breast cancer: a Danish population-based case–control study. Breast Cancer Res. 2012;14:R21.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Sacerdote P, Bianchi M, Gaspani L, et al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg. 2000;90:1411–1414.
   PubMed Web of Science ®Google Scholar
• Humphreys K. Avoiding globalisation of the prescription opioid epidemic. Lancet. 2017;390:437–439.
   PubMed Web of Science ®Google Scholar
• Sutradhar R, Lokku A, Barbera L. Cancer survivorship and opioid prescribing rates: a population-based matched cohort study among individuals with and without a history of cancer. Cancer. 2017;123:4286–4293.
   PubMed Web of Science ®Google Scholar
• Exadaktylos AK, Buggy DJ, Moriarty DC, et al. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology. 2006;105:660–664.
   PubMed Web of Science ®Google Scholar
• Biki B, Mascha E, Moriarty DC, et al. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology. 2008;109:180–187.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. Jco. 2002;20:4040–4049.
   PubMed Web of Science ®Google Scholar
• Myles PS, Peyton P, Silbert B, et al. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. BMJ. 2011;342:d1491.
   PubMed Web of Science ®Google Scholar
• Tsui BC, Rashiq S, Schopflocher D, et al. Epidural anesthesia and cancer recurrence rates after radical prostatectomy. Can J Anesth/J Can Anesth. 2010;57:107–112.
   PubMed Web of Science ®Google Scholar
• Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med. 1991;10:577–581.
   PubMed Web of Science ®Google Scholar
• Ahern TP, Lash TL, Sorensen HT, et al. Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case–control study. Breast Cancer Res. 2008;10:R102.
   PubMed Web of Science ®Google Scholar
• Ahern TP, Tamimi RM, Rosner BA, et al. Digoxin use and risk of invasive breast cancer: evidence from the Nurses' Health Study and meta-analysis. Breast Cancer Res Treat. 2014;144:427–435.
   PubMed Web of Science ®Google Scholar
• Biggar RJ, Wohlfahrt J, Oudin A, et al. Digoxin use and the risk of breast cancer in women. J Clin Oncol. 2011;29:2165–2170.
   PubMed Web of Science ®Google Scholar
• Flahavan EM, Sharp L, Bennett K, et al. A cohort study of digoxin exposure and mortality in men with prostate cancer. BJU Int. 2014;113:236–245.
   PubMed Web of Science ®Google Scholar
• Stenkvist B. Is digitalis a therapy for breast carcinoma? Oncol Rep. 1999;6:493–496.
   PubMed Web of Science ®Google Scholar
• Karasneh RA, Murray LJ, Mc Menamin UC, et al. Digoxin use after diagnosis of breast cancer and survival: a population-based cohort study. Breast Cancer Res Treat. 2015;151:661–669.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. Jco. 2010;28:3784–3796.
   PubMed Web of Science ®Google Scholar
• Cronin-Fenton DP, Damkier P, Lash TL. Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2013;10:107–122.
   Web of Science ®Google Scholar
• Lim YC, Li L, Desta Z, et al. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther. 2006;318:503–512.
   PubMed Web of Science ®Google Scholar
• Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95:1758–1764.
   PubMed Web of Science ®Google Scholar
• Ahern TP, Hertz DL, Damkier P, et al. Cytochrome P-450 2D6 (CYP2D6) genotype and breast cancer recurrence in tamoxifen-treated patients: evaluating the importance of loss of heterozygosity. Am J Epidemiol. 2017;185:75–85.
   PubMed Web of Science ®Google Scholar
• Cronin-Fenton DP, Lash TL. Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes. Expert Rev Clin Pharmacol. 2011;4:363–377.
   PubMedGoogle Scholar
• Lash TL, Lien EA, Sorensen HT, et al. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol. 2009;10:825–833.
   PubMed Web of Science ®Google Scholar
• Donneyong MM, Bykov K, Bosco-Levy P, et al. Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. BMJ. 2016;354:i5014.
   PubMed Web of Science ®Google Scholar
• Lash TL, Cronin-Fenton D, Ahern TP, et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst. 2011;103:489–500.
   PubMed Web of Science ®Google Scholar
• Ahern TP, Pedersen L, Cronin-Fenton DP, et al. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer. Epidemiol Biomarkers Prev. 2009;18:2562–2564.
   PubMed Web of Science ®Google Scholar
• Lash TL, Cronin-Fenton D, Ahern TP, et al. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol. 2010;49:305–312.
   PubMed Web of Science ®Google Scholar
• Fidler MM, Bray F, Soerjomataram I. The global cancer burden and human development: a review. Scand J Public Health. 2017 [Jun 1]. DOI:10.1177/140349481771540
   PubMed Web of Science ®Google Scholar